STOCK TITAN
  1. Home
  2. News
  3. PHIO

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MARLBOROUGH, Mass., Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th. The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Mr. Bitterman will discuss innovations in dermatological cancers, highlighting Phio's proprietary INASTYL™ platform. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.

Mr. Bitterman was recently appointed to his leadership role at Phio. He previously led Cutanea and Dermik in the development and commercialization of small molecule dermatological products.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

For additional information, visit the Company's website, www.phiopharma.com.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com  

Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com 

Cision View original content:https://www.prnewswire.com/news-releases/phio-showcases-innovations-in-dermatology-cancers-at-2023-dermatology-summit-in-san-francisco-301715760.html

SOURCE Phio Pharmaceuticals Corp.

Stock PHIO logo
Phio Pharmaceuticals Corp.

NASDAQ:PHIO

PHIO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PHIO Latest News

Apr 30, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Apr 22, 2024
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Apr 16, 2024
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Apr 11, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Apr 3, 2024
National Spotlight Features Phio’s Innovative RNAi Technology Platform

PHIO Stock Data

3.56M
4.55M
0.4%
11.04%
0.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MARLBOROUGH

About PHIO

phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.